Viscosupplementation Market Size Worth $12.94 Billion By 2032 | CAGR: 10.6%

The global viscosupplementation market size is expected to reach USD 12.94 billion by 2032, according to a new study by Polaris Market Research. The report “Viscosupplementation Market Share, Size, Trends, Industry Analysis Report, By Product (Three Injection, Five Injection, Single Injection); By End-Use; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Viscosupplementation, a safe non-surgical approach for knee arthritis, can also be complemented by a bone growth stimulator based on bone condition. This treatment is particularly effective for individuals in the early stages of arthritis, involving the injection of a gel-like substance, hyaluronic acid. Hyaluronic acid naturally exists in the synovial fluid enveloping joints, serving as a lubricant to enable flexible bone movement and alleviate discomfort.

As per the World Health Organization (WHO), the global population of individuals aged 60 and above is anticipated to rise by 1.4 billion by 2030 worldwide. Advancing age brings about various health issues in the elderly, with one of the most common being bone and joint-related problems such as osteoarthritis, osteoporosis, and others, resulting in challenges like difficulty in movement and walking. Many elderly individuals become reliant on personal mobility devices due to transportation difficulties, thereby increasing the cost of these devices. It is widely acknowledged that joint mobility decreases and stiffness increases with age, accompanied by a reduction in lubricating fluid within the joints over time. Consequently, the increasing prevalence of the geriatric population is driving the demand for viscosupplementation treatment.

The advent of the COVID-19 pandemic significantly influenced the viscosupplementation market as hospital and ambulatory surgical center visits declined due to lockdown measures imposed globally. These restrictions led to the suspension of non-emergency procedures in hospitals, affecting patients' lives. Consequently, the market under consideration is anticipated to be impacted during the pandemic era. However, as procedures resume, hospital visits increase and COVID-19 restrictions ease, the market is expected to regain its potential over time.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/viscosupplement-market/request-for-sample

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Viscosupplementation devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Viscosupplementations throughout the forecast period.

Viscosupplementation Market Report Highlights

• In 2022, the Three Injection segment dominated the market in terms of revenue. The three-injection procedure stands out as the preferred method for treating osteoarthritis, chosen by medical practitioners for its effectiveness. This approach is commonly favored to reduce the necessity for total knee replacement surgery in cases of osteoarthritis, influencing the market share. The availability of various three-injection segments further contributes to this trend. Additionally, the approval of numerous clinical trials showcasing positive results for three-injection procedures in osteoarthritis treatment adds to the segment's significance.
• During the forecast period, the highest market share was attributed to the Orthopedic Clinics/ASCs segment. This dominance is driven by the rising demand for outpatient surgeries, with orthopedic clinics focusing on comprehensive musculoskeletal care encompassing both surgical and nonsurgical interventions for the spine, joints, ligaments, bones, muscles, and nerves. The notable increase in the prevalence of osteoarthritis among the elderly population is a key factor expected to contribute significantly to the growth of this segment.
• In 2022, Asia Pacific emerged as the dominant market, with its growth being prominently driven by the presence of a susceptible geriatric population prone to osteoarthritis. Furthermore, the market expansion is bolstered by various initiatives focused on strengthening the overall market landscape in the region.
• The global key market players include Anika Therapeutics, Inc., DePuy Synthes, F.Hoffmann-La Roche Ltd., Ferring Pharmaceuticals B.V., Fidia Farmaceutici S.p.A, LG Life Sciences Ltd., Lifecore Biomedical, Sanofi, Seikagaku Corp., Smith & Nephew PLC, Zimmer Biomet.

Polaris Market Research has segmented the Viscosupplementation market report based on product, end-use, and region:

Viscosupplementation, Product Outlook (Revenue - USD Billion, 2019 - 2032)

• Three Injection
• Five Injection
• Single Injection

Viscosupplementation, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

• Orthopedic Clinics/ASCs
• Hospitals

Viscosupplementation, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

• North America

• U.S.
• Canada

• Europe

• Germany
• UK
• France
• Italy
• Spain
• Russia
• Netherlands

• Asia Pacific

• China
• India
• Japan
• South Korea
• Indonesia
• Malaysia

• Latin America

• Argentina
• Brazil
• Mexico

• Middle East & Africa

• UAE
• Saudi Arabia
• Israel
• South Africa

Viscosupplementation Market Report Scope